Curated News
By: NewsRamp Editorial Staff
October 22, 2026
Annovis Bio to Present Buntanetap Data at CTAD 2026
TLDR
- Annovis Bio will showcase buntanetap's Phase 3 progress at CTAD 2026, positioning ANVS ahead of a pivotal 2027 data readout and NDA.
- Buntanetap is a once-daily oral therapy that inhibits translation of neurotoxic proteins like amyloid beta, tau, and alpha-synuclein via RNA targeting.
- Annovis Bio's buntanetap aims to halt neurodegeneration and improve cognition and motor function for Alzheimer's and Parkinson's patients.
- Annovis Bio will present three CTAD 2026 sessions, including AI used to predict blood-brain barrier permeability of late-stage Alzheimer's drug candidates.
Impact - Why it Matters
Annovis Bio’s upcoming presentations at CTAD 2026 underscore the growing momentum behind buntanetap, a multi-target oral therapy that could reshape the treatment landscape for Alzheimer’s and Parkinson’s diseases. By tackling multiple neurotoxic proteins simultaneously, buntanetap offers a novel approach that may halt disease progression rather than merely managing symptoms. The inclusion of AI-driven blood-brain barrier permeability predictions further highlights the company’s innovative edge in drug development. With a pivotal Phase 3 readout expected in early 2027 and an NDA on the horizon, these presentations could be a catalyst for investor confidence and partnership opportunities. For patients and caregivers, the progress signals hope for a convenient, once-daily oral treatment that addresses the underlying pathology of devastating neurodegenerative conditions.
Summary
Annovis Bio (NYSE: ANVS) has announced it will deliver three presentations at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place November 16–19, 2026, in Boston. The presentations will spotlight the company’s investigational oral therapy buntanetap, covering its mechanism of action targeting neurotoxic proteins, the design and baseline characteristics of its pivotal Phase 3 study in early Alzheimer’s disease, and the use of artificial intelligence to predict blood-brain barrier permeability for late-stage Alzheimer’s drug candidates. The program features an oral presentation on November 19 by Alexander Morin, director of strategic communications, along with two poster presentations on November 16–17, one of which will be given by Chief Scientific Officer Cheng Fang.
According to Annovis, these presentations reflect significant progress in the buntanetap development program as the company approaches a pivotal clinical data readout in early 2027 and prepares for a New Drug Application. Buntanetap (formerly posiphen) is a once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins—including APP and amyloid beta, tau, alpha-synuclein, and TDP-43—through a specific RNA-targeting mechanism. By addressing underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients with Alzheimer’s and Parkinson’s disease. For more information, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X.
The full press release is available at https://nnw.fm/2k4SQ. The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS. The announcement was distributed by NetworkNewsWire (NNW), a specialized communications platform focused on financial news and content distribution for private and public companies and the investment community. NNW is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Annovis Bio to Present Buntanetap Data at CTAD 2026
